Search Result

Results for "

human SGLT2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SGLT (22) Endogenous Metabolite (2) GLP Receptor (1) GLUT (2) Isotope-Labeled Compounds (4) Reactive Oxygen Species (ROS) (1) Reference Standards (4)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (1) Metabolic Disease (23)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15409

Empagliflozin Maximum Cited Publications 89 Publications Verification BI 10773	SGLT	Infection Metabolic Disease Cancer
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-N0142

Phloretin 20+ Cited Publications NSC 407292; RJC 02792	SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM，respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-17638

Mizagliflozin 5 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective *SGLT1* inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-14894

Ipragliflozin 5+ Cited Publications ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .

HY-15409R

Empagliflozin (Standard) BI 10773 (Standard)	Reference Standards SGLT	Metabolic Disease
Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-13413

Tofogliflozin hydrate 4 Publications Verification CSG-452 hydrate	SGLT Reactive Oxygen Species (ROS)	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse *SGLT2* . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells .

HY-123797

KGA-2727 2 Publications Verification	SGLT	Metabolic Disease
KGA-2727 is a first selective, high-affinity and orally active *SGLT1* inhibitor with K_is of 97.4 nM and 43.5 nM for *human* and rat SGLT1, respectively. The selectivity ratios (K_i for SGLT2/K_i for *SGLT1) of KGA-2727 are 140 (human*) and 390 (rat). KGA-2727 has antidiabetic efficacy .

HY-I1120

SGLT2-IN-1	SGLT	Metabolic Disease
SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC₅₀ of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin .

HY-15409S

Empagliflozin-d4 BI 10773-d₄	SGLT	Metabolic Disease
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-14902

Tofogliflozin 4 Publications Verification CSG452	SGLT	Metabolic Disease
Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

HY-101122

LX2761	SGLT GLP Receptor	Metabolic Disease
LX2761 is an orally active, dual *SGLT1/SGLT2* inhibitor with IC₅₀ values of 2.2 nM and 2.7 nM against human *SGLT1* and *SGLT2, respectively. LX2761 locks human* SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research .

HY-106158

T-1095	SGLT	Metabolic Disease
T-1095 is a selective and orally active Na ⁺-glucose cotransporter (SGLT) inhibitor with IC₅₀s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research .

HY-13414

Remogliflozin Remogliflozin A	SGLT	Metabolic Disease
Remogliflozin is a potent and selective inhibitor of *SGLT2* (sodium-glucose cotransporter 2) with K_is of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945) .

HY-N0142R

Phloretin (Standard) 20+ Cited Publications NSC 407292 (Standard); RJC 02792 (Standard)	Reference Standards SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-I1120R

SGLT2-IN-1 (Standard)	Reference Standards SGLT	Metabolic Disease
SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC₅₀ of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin.

HY-14894R

Ipragliflozin (Standard) ASP1941 (Standard)	Reference Standards SGLT	Metabolic Disease
Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-15409S1

Empagliflozin-13C6 BI 10773-¹³C₆	Isotope-Labeled Compounds	Metabolic Disease Cancer
Empagliflozin- ¹³C₆ (BI 10773- ¹³C₆) is ¹³C labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-15409S2

Empagliflozin-d6 BI 10773-d₆	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Empagliflozin-d₆ (BI 10773-d₆) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-14894S2

Pragliflozin-13C6 ASP1941-¹³C₆	Isotope-Labeled Compounds SGLT	Metabolic Disease
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-125327

YM-543	SGLT	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-166652S

Empagliflozin-d8	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Empagliflozin-d₈ is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-17604

Bexagliflozin 1 Publications Verification EGT1442; EGT0001442; THR-1442	SGLT	Cardiovascular Disease Metabolic Disease
Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC₅₀ values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA_1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0142

Phloretin 20+ Cited Publications NSC 407292; RJC 02792	Classification of Application Fields Rosaceae Plants Dihydrochalcones Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Malus pumila Mill. Phenols Polyphenols Disease Research Fields Source Classification Cancer	SGLT Endogenous Metabolite GLUT
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM，respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-N0142R

Phloretin (Standard) 20+ Cited Publications NSC 407292 (Standard); RJC 02792 (Standard)	Structural Classification Human Gut Microbiota Metabolites Flavonoids Classification of Application Fields Malus pumila Mill. Rosaceae Phenols Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	Reference Standards SGLT Endogenous Metabolite GLUT
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

Cat. No.	Product Name	Chemical Structure

HY-15409S

Empagliflozin-d4
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-15409S1

Empagliflozin-13C6
Empagliflozin- ¹³C₆ (BI 10773- ¹³C₆) is ¹³C labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-15409S2

Empagliflozin-d6
Empagliflozin-d₆ (BI 10773-d₆) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-14894S2

Pragliflozin-13C6
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-166652S

Empagliflozin-d8
Empagliflozin-d₈ is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

human SGLT2

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products